Form 4 Filing for Lucas Svetlana

Lucas Svetlana, a director at Jasper Therapeutics, Inc. (JSPR), was granted a stock option to purchase 7,500 shares of common stock on July 31, 2026. The option has an exercise price of $0.63 and will vest in full on August 4, 2027, subject to continued service. This grant was made automatically under the company's Non-Employee Director Compensation Policy. The filing also notes that Svetlana acquired these options as a director, with no other ownership affiliations reported. The transaction is reported on Form 4.